The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Target Validation, 2011The Unfolded Protein Response (UPR) Chaperone GRP78/BiP as a Therapeutic Target for Alpha-Synuclein Toxicity
Objective/Rationale:
Glucose regulating protein 78 (GRP78/BiP), also known as BiP or HSPA5, is a member of the HSP70 family of chaperones. Along with its role in protein folding, GRP78/BiP is also... -
Target Validation, 2011Modulation of Microglial Activation
Objective/Rationale:
Over-activation of immune cells in the brain can lead to increased neuron loss in diseases such as Parkinson’s. Fractalkine is a protein that is a key player in controlling... -
MJFF Research Grant, 2011Increasing the Sensitivity of LRRK2 Assays: Development of Proximity Ligation Assays for LRRK2
Objective/Rationale:
Inherited mutations in the enzyme LRRK2 are known to cause Parkinson’s disease (PD). Measuring the enzyme activity of LRRK2 in patient biological samples is difficult due to the... -
Rapid Response Innovation Awards, 2011How Does GBA1 Dysfunction Influence Parkinson's Disease?
Objective/Rationale:
Recent studies have revealed that defects in a gene known as GBA1 are the most common genetic cause of Parkinson’s disease (PD). The GBA1 gene is known to play a role in fat... -
Target Validation, 2011Regulatory T Cells as Modulators of Microglia's Inflammatory Response
Objective/Rationale:
Evidence in humans and in research models support a role for the immune system in the progression of Parkinson's disease. Local brain immune cells, called microglia, as well as... -
Clinical Intervention Awards, 2011First-in-human Trial to Assess the Safety and Tolerability of PD01, the First Alpha-synuclein-based AFFITOPE® Parkinson's Vaccine
Objective/Rationale:
Parkinson’s disease (PD) is characterized by the presence of protein aggregates called Lewy bodies, with a major component of the protein alpha-synuclein. This fact and...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.